Chairs: N. Tsoukalas, D. Papageorgiou
12.00-12.20 Presenter: M. Lavdaniti
Abstract 11001: Outcomes of an electronic patient-reported outcomes (ePRO) - based symptom management program (eSyM): A cluster randomized trial.
Abstract 11003: Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment.
12.20-12.40 Presenter: C. Ntola
Abstract 12006: A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors
Abstract 12007: Romiplostim for chemotherapyinduced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).
12.40-13.00 Discussants: Ν. Tsoukalas, D. Papageorgiou
13.00-14.10 Session 2 | Head and Neck Cancer (HNC)
Chairs: A. Kotsakis, V. Lachanas
13.00-13.30 Presenter: P. Katsaounis
Abstract 6012: Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.
Abstract LBA2: NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
Abstract LBA6003: PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.
13.30-13.50 Presenter: E. Chantzara
Abstract 6001: Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
Abstract 6008: Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial.
13.50-14.10 Discussant: A. Psyrri
Chairs: C. Kosmas, C. Panopoulos
Presenter: A. Stribakos
Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations
Chairs: G. Rigakos, S. Labropoulos
15.40-16.00 Presenter: D. Kalapanida
Abstract 2011: Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.
Abstract 2002: Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.
16.00-16.20 Discussant: G. Rigakos
Chairs: A. Psyrri, P. Katsaounis
16.20-16.50 Presenter: G. Karkaletsos
Abstract 3002: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
Abstract 3001: Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
Abstract 3004: Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
16.50-17.10 Presenter: A. Lazarou
Abstract 2501: First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
Abstract 2513: Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
17.10-17.30 Presenter: S. Kokkali
Abstract 3007: Ultra-sensitive pan-cancer molecular residual disease molecular residual disease assessment using whole-genome sequencing-based personalized ctDNA panel: Initial results from the MONSTAR-SCREEN-3 project.
Abstract 3006: Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
17.30-17.40 Discussant E. Kontopodis
Chairs: A. Koutras, I. Kotteas
18.00-18.20 Presenter: K. Rapti
Abstract 505: 15-year outcomes for women with premenopausal hormone
receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.
Abstract 507: The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.
18.20-18.40 Presenter: A. Kokkalis
Abstract LBA500: De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
Abstract 501: Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/ Compass HER2 pCR trial.
18.40-19.00 Discussant A. Nikolaidi
Chairs: V. Barbounis, E. Galani
19.00-19.20 Presenter: C. Aidarinis
Abstract LBA1000: Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
Abstract LBA4: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
19.20-19.40 Presenter: N. Asimakopoulou
Abstract LBA109: Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
Abstract LBA1008: Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09.
19.40- 20.00 Discussant E. Saloustros
Chairs: A. Stribakos, I. Samaras
09.00-09.40 Presenter: Μ. Avgoustidou
Abstract LBA3500: First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses.
Abstract 3505: Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).
Abstract 3501: Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.
Abstract LBA1: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
09.40-10.00 Discussant: G. Oikonomopoulos
Chairs: P. Papakostas, Μ. Theochari
10.00-10.20 Presenter: M. Drizou
Abstract LBA5: Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
Abstract 4000: Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
10.20-10.40 Presenter: A. Markou
Abstract LBA4002: Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized,
phase 3 DESTINY-Gastric04 study.
Abstract LBA4005: PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
10.40-11.00 Discussant G. Papaxoinis
Chairs: C. Kosmas, G. Sotiropoulos
Presenter: N. Machairas
Liver Transplantation in Metastatic Cancer
Discussion
Chairs: D. Bafaloukos, A. Tzovaras
12.00-12.20 Presenter: A. Laskarakis
Abstract LBA9507: A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013).
Abstract 9506: DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM) - Final clinical results.
12.20-12.50 Presenter: I. Gazouli
Abstract LBA9508: Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first line treatment for metastatic melanoma: Results of the DANTE phase III trial.
Abstract LBA9500: Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
Abstract 9515: Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
12.50-13.00 Discussant D. Ziogas
Chairs: M. Nikolaou, E. Saloustros
13.00-13.30 Presenter: S. Goura
Abstract 10509: Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.
Abstract 10510: Germline pathogenic variants in cancer predisposition genes and overall survival of women with breast cancer.
Abstract 10500: Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.
13.30-13.40 Panel Discussion
Chairs: C. Papadimitriou, M. Liontos
14.30-14.50 Presenter: E. Eleftherakis-Papaiakovou
Abstract LBA5500: TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7).
Abstract 5511: Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.
14.50-15.00 Presenter: E. Chantzara
Abstract LBA5504: Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
15.00-15.20 Discussant: M. Rovithi
Chairs: A. Koumarianou, A. Boutis
15.20-15.40 Presenter: E.-G. Fergadis
Abstract 8006: Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
Abstract LBA8008: Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial.
15.40-15.50 Presenter: A. Pantazopoulos
Abstract 8001: Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.
15.50-16.10 Discussant: A. Grivas
Chairs: A. Kotsakis, A. Charpidou
16.10-16.30 Presenter: S. Chrysoglou
Abstract 8506: Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.
Abstract LBA8505: Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.
16.30-16.50 Presenter: G. Christodoulopoulos
Abstract LBA8000: Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
Abstract 8500: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
16.50-17.10 Discussant: G. Evangelou
Chairs: M. Tsiatas, I. Kotsantis
17.30-17.50 Presenter: T. Tegos
Abstract LBA500 acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
Abstract 5001: Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
17.50-18.10 Presenter: E. Christakou
Abstract 4505: Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial.
Abstract 4514: Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).
18.10-18.40 Presenter: N. Cholis
Abstract 4500: Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
Abstract 4503: Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
Abstract 4517: Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on disease stage from the CREST study.
18.40-19.00 Discussant: E. Lianos















